A type of cancer therapy called immunotherapy works by assisting the body’s immune system in battling cancer. There are numerous forms of cancer that can benefit from cancer immunotherapy. For those with many types of cancer who often have a poor diagnosis, it helps to improve outcomes. A universal treatment for cancer, immunotherapy enables the immune system to identify and attack cancer cells. For patients with cancer, including but not limited to melanoma, bladder cancer, lung cancer, kidney cancer, prostate cancer, leukaemia, and lymphoma, the U.S. Food and Drug Administration (FDA) has approved a variety of immunotherapies.
Market Statistics:
By the end of 2022, the global market for cancer immunotherapy is anticipated to be worth US$ 102,122.1 Mn.
Drivers:
Major factors anticipated to drive growth of the global cancer immunotherapy market over the forecast period include increased research and development activities in the field of cancer immunotherapy and high adoption of cutting-edge cancer therapies. There are numerous forms of cancer that can benefit from cancer immunotherapy. Immunotherapy is presently used to treat a wide variety of cancers. Amgen’s LUMAKRAS (Sotorasib), which treats patients with KRAS G12C, a mutation that causes locally progressed or metastatic non-small cell lung cancer, received FDA approval in May 2021. (NSCLC). The first and only targeted therapy for NSCLC is LUMAKRAS.
Request Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/5274
Opportunities:
The worldwide cancer immunotherapy industry is likely to see considerable growth potential as the incidence and prevalence of cancer increase. The World Health Organization (WHO) reports that in 2020, cancer was the greatest cause of death globally. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. Cancer immunotherapy is becoming more and more popular as cancer incidence and prevalence rise. Additionally, the Breast Cancer Research Foundation projects that the number of women in the United States who will receive a breast cancer diagnosis in 2022 will be around 287,850, making it the most frequent cancer among women in the country.
Restraints:
Some significant factors that are anticipated to impede the growth of the global cancer immunotherapy market include the high cost of cancer immunotherapy, the negative effects of cancer treatment, and strict regulatory standards. The price of cancer treatment might vary depending on a number of variables that are very important in determining the price of immunotherapy in India. The price of each session, however, fluctuates and ranges depending on the therapeutic circumstances. Immunotherapy sessions in India cost between INR 150,000 (US$ 2,091) and 455,000 (US$ 6500).
Impact:
Due to a lack of and irregular supply of cancer immunotherapy drugs, the COVID-19 outbreak has had a significant negative influence on the growth of the market for cancer immunotherapy (due to nationwide lockdown and travel restrictions). Additionally, certain biopharmaceutical firms, including Eli Lilly and Company and Merck & Co. Inc., disclosed delays in clinical trials. Over 200 interventional oncology trials were put on hold in March and April 2020 as a result of the worldwide pandemic, according to ClinicalTrials.gov.
Key Takeaways:
The market for cancer immunotherapy was estimated at US$ 93,407.0 million in 2021 and is anticipated to grow at a CAGR of 9.9% from 2022 to 2028 to reach US$ 180,137.7 million.
In terms of therapy type, the monoclonal antibodies segment dominated the global market for cancer immunotherapy in 2021, holding a 47.1% market share in terms of value. Increasing approval and the introduction of new products are anticipated to drive segment growth over the course of the forecast period.
We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/5274
Market Trends:
One in four cancer diagnoses among women globally is breast cancer. Women are also more likely to get thyroid, cervical, lung, and colorectal cancer. The market is predicted to develop as a result of the rise in demand for safe and efficient cancer treatments, such as immunotherapy medications, throughout the course of the forecast period. Due to this, market participants are concentrating on the creation of innovative immunotherapy medications, and this pattern is anticipated to persist over the forecast period.
Competitive Landscape:
Bristol-Myers Squibb Company, Novartis AG, OSE Immunotherapeutics SA, Merck & Co. Inc., Amgen Inc., F-Hoffmann La Roche, Astellas Pharma Inc., Eli Lilly and Company, AstraZeneca, and Bayer AG, are a few of the major companies competing in the global market for cancer immunotherapy.
Recent Developments:
AstraZeneca and Accent Therapies announced their partnership in June 2020 with the goal of discovering, creating, and commercialising revolutionary therapeutics that target RNA-modifying proteins to treat cancer.
The U.S. FDA granted Breakthrough Treatment designation for PADCEV, in conjunction with the immune therapy pembrolizumab, in First-line advanced bladder cancer, Astellas Pharma Inc. and Seattle Genetics Inc. reported in February 2020.
Amgen Inc. and BeiGene formed a strategic partnership in January 2020 to increase its cancer business in China. To speed up the molecular testing for patients with non-small cell lung cancer, Amgen Inc. furthermore worked with Guardant Health Inc. and Qiagen.
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Cancer Immunotherapy Market Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Cancer Immunotherapy Market Industry Impact
Chapter 2 Global Cancer Immunotherapy Market Competition by Types, Applications, and Top Regions and Countries
2.1 Global Cancer Immunotherapy Market (Volume and Value) by Type
2.3 Global Cancer Immunotherapy Market (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Cancer Immunotherapy Market Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Cancer Immunotherapy Market Market Analysis
Chapter 6 East Asia Cancer Immunotherapy Market Market Analysis
Chapter 7 Europe Cancer Immunotherapy Market Market Analysis
Chapter 8 South Asia Cancer Immunotherapy Market Market Analysis
Chapter 9 Southeast Asia Cancer Immunotherapy Market Market Analysis
Chapter 10 Middle East Cancer Immunotherapy Market Market Analysis
Chapter 11 Africa Cancer Immunotherapy Market Market Analysis
Chapter 12 Oceania Cancer Immunotherapy Market Market Analysis
Chapter 13 South America Cancer Immunotherapy Market Market Analysis
Chapter 14 Company Profiles and Key Figures in Cancer Immunotherapy Market Business
Chapter 15 Global Cancer Immunotherapy Market Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology
Direct Buy This Premium Research Report, Click Here @ https://www.coherentmarketinsights.com/insight/buy-now/5274
About US
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us
Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, United States
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com